Adlai Nortye Ltd. announced an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. AN4035 showed strong intracellular payload retention, inducing regression in cancer cell lines. AN4035 has a favorable toxicology profile in monkeys and is designed to reduce systemic toxicities. The presentation details the discovery of AN4035, a novel CEACAM5-targeting antibody drug conjugate armed with a pan-RAS(ON) inhibitor payload. Adlai Nortye aims to deliver transformative oncology therapies with a wider therapeutic window for difficult-to-treat cancers. The presentation will be on October 25, 2025, in Boston, MA. For more information, visit the AACR website and conference app.

Read more at GlobeNewswire: Adlai Nortye to Present Short Talk on AN4035 Preclinical